Response to Eriksson et al A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients
Transpl Infect Dis
.
2021 Apr;23(2):e13493.
doi: 10.1111/tid.13493.
Epub 2020 Oct 27.
Authors
Rachel Souza Dawson
1
,
Kristen Feemster
1
,
E David G McIntosh
2
,
Ulrike K Buchwald
3
Affiliations
1
Global Medical and Scientific Affairs (Vaccines), Merck & Co., Inc., Kenilworth, NJ, USA.
2
MSD, UK.
3
Global Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA.
PMID:
33047468
DOI:
10.1111/tid.13493
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Humans
Kidney Transplantation* / adverse effects
Pneumococcal Infections* / prevention & control
Polysaccharides
Transplant Recipients
Vaccination
Substances
Polysaccharides
Grants and funding
Merck